There has been substantial investment and commercial scale-up of circulating tumor DNA technologies, indicating the field is moving rapidly from research methods (4 years ago) to clinically deployed and commercialized applications.
factualpending
Speaker
Unknown Speaker (Oncologist)Evidence Quote
“there's been a real explosion in terms of investment in this area and now scale up of technologies that are you know commercially relevant”
Created: 8/11/2026, 1:43:50 AM
Your notes
Loading notes...